Cronos Group Inc

Cronos Group Inc(CRON)の株式分析

$3.445

+0.056 (+1.62%)終値時点

Loading chart…
高値
3.465
始値
3.390
出来高加重平均価格
3.43
出来高
995.56K
時価総額
893.91M
安値
3.373
売買代金
3.41M
EV/EBITDA(TTM)
9.78

Cronos Group Inc. is a global cannabinoid company focused on consumer goods products through research and development and innovation. The Company's diverse international brand portfolio includes Spinach, PEACE NATURALS, Lord Jones, LIT, and C.O.G. Spinach is a mainstream adult-use cannabis brand with a portfolio that includes cannabinoid products in a wide range of formats, including dried flower, pre-rolls, vaporizers, and edibles. Lord Jones is a premium cannabis brand. The Lord Jones brand portfolio includes cannabis products in the pre-roll, vaporizer concentrates and edible categories. The Lord Jones brand products are available in the Israeli medical market with cannabis flower products. PEACE NATURALS is a global medical brand engaged in producing cannabis products. LIT is a value‑driven medical cannabis brand, which offers a focused lineup of dried flower products sold in medical markets across Israel, Germany and the United Kingdom.

thecronosgroup.com

AI分析 of Cronos Group Inc (CRON)

買い

Cronos Group Inc appears to be a good buy right now, especially considering its current price of $3.21 and a forward P/E ratio of 28.74. The company reported a remarkable 58% year-over-year increase in net revenue for Q2 2026, reaching $53 million, and its gross margin improved to 53.69%. These figures indicate strong financial performance and growth potential. However, the main risk is its current RSI of 45.12, which suggests it may be nearing oversold conditions, indicating potential volatility.

アナリスト評価(1)

-21.04% 下落余地
中立
0 買い
1 中立
0 売り
現在: 3.45
安値
2.30
平均
2.72
高値
3.14

TD Securities

2026-09-28

目標株価

$7

買い

TD Securities

2026-05-12

目標株価

—

買い

TD Securities

2026-02-24

目標株価

$4.50

買い

Canaccord

2026-01-27

目標株価

$4.25

買い

CIBC

2024-05-15

目標株価

$3.5

買い

バリュエーション指標

Cronos Group Inc(CRON)の現在の予想PERは28.74で、5年平均は382.94です。

予想PER

適正
5年平均 P/E
382.94
現在のP/E
28.74
割高
1594.52
割安
-828.64

予想EV/EBITDA

適正
5年平均 EV/EBITDA
-3.32
現在のEV/EBITDA
9.78
割高
16.70
割安
-23.34

予想PSR

割安
5年平均 P/S
7.38
現在のP/S
3.03
割高
10.65
割安
4.10

Alphio AI による CRON の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%CRON

$3.12

シナリオ価格

基

基本

基本 · 50%CRON

$2.76

シナリオ価格

弱

弱気

弱気 · 25%CRON

$2.38

シナリオ価格

CRON を保有するクジラ

A

Altria Group, Inc.

+ を保有CRONBUD

+6.40%

3か月リターン

イベントタイムライン

2026-06-30 (ET)

17:30:00

Cronos Group Appoints ATB Capital Markets for Share Repurchases

2026-06-16 (ET)

16:30:00

Cronos Group Files Normal Course Issuer Bid

2026-05-11 (ET)

07:50:00

Cronos Reports Q1 Revenue of $45.21M

2026-04-23 (ET)

13:10:00

Roth Capital: Cannabis Products Rescheduled to Schedule 3

10:30:00

Trump Orders Medical Marijuana Products to Schedule III

ニュース

CRON のよくある質問 — Alphio AI が回答

Cronos Group Inc. is a global cannabinoid company focused on consumer goods products through research and development and innovation. The Company's diverse international brand portfolio includes Spinach, PEACE NATURALS, Lord Jones, LIT, and C.O.G. Spinach is a mainstream adult-use cannabis brand with a portfolio that includes cannabinoid products in a wide range of formats, including dried flower, pre-rolls, vaporizers, and edibles. Lord Jones is a premium cannabis brand. The Lord Jones brand portfolio includes cannabis products in the pre-roll, vaporizer concentrates and edible categories. The Lord Jones brand products are available in the Israeli medical market with cannabis flower products. PEACE NATURALS is a global medical brand engaged in producing cannabis products. LIT is a value‑driven medical cannabis brand, which offers a focused lineup of dried flower products sold in medical markets across Israel, Germany and the United Kingdom. It operates in the Healthcare sector (MEDICINAL CHEMICALS & BOTANICAL PRODUCTS industry).

Cronos Group Inc appears to be a good buy right now, especially considering its current price of $3.21 and a forward P/E ratio of 28.74. The company reported a remarkable 58% year-over-year increase in net revenue for Q2 2026, reaching $53 million, and its gross margin improved to 53.69%. These figures indicate strong financial performance and growth potential. However, the main risk is its current RSI of 45.12, which suggests it may be nearing oversold conditions, indicating potential volatility.

1 analysts cover CRON: 0 rate it Buy, 1 Hold and 0 Sell. The average price target is 2.72.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める